Press Releases

Press Releases

MALVERN, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the Compensation Committee of the Board of Directors of
September 16, 2022
Conference Call and Webcast Today at 8:30 a.m. ET Dosing patients in U.S. Phase 2/3 COVAXIN ™ (BBV152) clinical trial Completed dosing of patients in Cohort 1 of OCU400 gene therapy product candidate Expanding product pipeline with the regenerative medicine cell therapy program NeoCart ® MALVERN,
August 5, 2022